Stock Region Watchlist
Stock Region Watchlist Newsletter - Tuesday, February 4, 2025
Stock Region Watchlist Newsletter - Tuesday, February 4, 2025
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
Disclaimer: The information provided in this newsletter is for educational purposes only and should not be considered financial advice. Always consult a financial advisor before making investment decisions.
Pfizer ($PFE)
Earnings Beat
Pfizer surprised Wall Street with Q4 2024 revenue of $17.76 billion, outpacing expectations thanks to strong adjusted earnings per share (EPS).
Cost-Cutting Success
With $4.5 billion in net cost savings, the company has successfully offset declines in its COVID-19 business, signaling resilience.
Pipeline Potential
All eyes are on Pfizer’s experimental obesity pill, danuglipron, which could make waves in the booming weight loss market.
Growth Beyond COVID
Revenue from non-COVID products continues to shine, particularly from cancer drugs and the blood thinner Eliquis.
Key Levels
Upside: Above $26.80
Downside: Below $26.20
PepsiCo ($PEP)
Earnings Consistency
PepsiCo exceeded earnings per share (EPS) expectations with $1.96.
Revenue Trends
While revenue dipped slightly, the company’s stronghold in the snack and beverage market remains intact.
Investor Outlook
Long-term investors favor PepsiCo for its robust dividend history and operational efficiency, reinforcing its image as a stable performer.
Key Levels
Upside: Above $147.00
Downside: Below $146.53
Palantir ($PLTR)
AI Revolution Leadership
Palantir experienced explosive growth with Q4 2024 revenue up 36%, driven by its dominance in AI-driven solutions.
Bright Prospects
Looking ahead, the company projects 2025 revenue of $3.75 billion, with an anticipated 54% growth in its commercial division.
Market Buzz
Strong margins and positive guidance have earned Palantir analyst upgrades and rising price targets, fueling investor enthusiasm.
Record-Breaking Momentum
The stock hit an all-time high this week, propelled by its reputation as a leader in the AI sector.
Key Levels
Upside: Above $103.85
Downside: Below $97.57
Merck ($MRK)
Innovative Leadership
Merck remains a top player in pharmaceutical innovation, particularly in oncology and vaccine treatments.
Steady Financials
Known for consistent earnings, the company continues to deliver growth in key therapeutic areas.
Defensive Play
For investors seeking stability during volatile times, Merck offers reliable options with consistent returns.
Key Levels
Upside: Above $93.00
Downside: Below $90.99
Thank you for reading Stock Region’s weekly newsletter. Stay informed and make smart market moves!
Disclaimer: All the information shared above is provided for educational purposes only. It is not intended as investment advice. Consult a licensed financial advisor to guide your investment decisions.
We are working endlessly to provide free insights on the stock market every day, and greatly appreciate those who are paid members supporting the development of the Stock Region mobile application. Stock Region offers daily stock and option signals, watchlists, earnings reports, technical and fundamental analysis reports, virtual meetings, learning opportunities, analyst upgrades and downgrades, catalyst reports, in-person events, and access to our private network of investors for paid members as an addition to being an early investor in Stock Region. We recommend all readers to urgently activate their membership before reaching full member capacity (500) to be eligible for the upcoming revenue distribution program. Memberships now available at https://stockregion.net